<p>2025 年 7 月 8 日- 上午 9:07</p>
<p>馬薩諸塞州比勒裏卡 --（商業資訊）--Quanterix Corporation（“Quanterix” 或 “公司”）（納斯達克：QTRX），一家通過超靈敏生物標誌物檢測推動科學發現的公司，今天宣佈已完成之前宣佈的對 Akoya Biosciences, Inc.的收購，確立了在神經學、腫瘤學和免疫學市場早期疾病檢測的領先地位。</p>
<p>根據 4 月 29 日宣佈的修訂合併協議，Quanterix 向 Akoya 的股東和其他 Akoya 股權獎勵持有者發行了約 780 萬股普通股，並支付了約 2000 萬美元的現金，總計。</p>
<p>Quanterix 首席執行官 Masoud Toloue 博士表示：“收購 Akoya 使我們能夠提供全面的蛋白質生物標誌物解決方案，利用血液和組織中的特徵，提供對患者疾病的更全面和預測性的視角。這筆交易將我們的產品組合擴展到新市場，並預計將我們的可服務市場從 10 億美元擴大到 50 億美元。我們相信，合併後的業務將受益於顯著的規模、強大的資產負債表以及到 2026 年實現盈利的加速路徑。”</p>
<p><strong>董事會和管理層任命</strong></p>
<p>如之前所宣佈的，Masoud Toloue 和 Vandana Sriram 將繼續擔任合併公司的首席執行官和首席財務官。</p>
<p>根據合併協議的條款，Akoya 指定了兩名董事 Scott Mendel 和 Myla Lai-Goldman 博士加入 Quanterix 董事會，Quanterix 在交易完成時任命 Mendel 先生和 Lai-Goldman 博士為其董事會成員。Mendel 先生擁有超過 30 年的財務和運營經驗，最近擔任 GenMark Diagnostics 的首席執行官和總裁。Lai-Goldman 博士是診斷行業的先驅和領導者，曾在 Labcorp 及其前身公司 Roche Biomedical Laboratories 擔任多個領導職務。</p>
<p>Mendel 先生和 Lai-Goldman 博士將取代在交易完成前立即辭去 Quanterix 董事會職務的 Martin D. Madaus 博士和 Sarah Hlavinka。Quanterix 感謝 Madaus 博士和 Hlavinka 女士對公司的諸多貢獻和奉獻。</p>
<p><strong>資產負債表</strong></p>
<p>在完成 Akoya 交易時，Quanterix 在償還 Akoya 債務和交易相關費用後，擁有約 1.63 億美元的現金。</p>
<p><strong>關於 Quanterix</strong></p>
<p>從發現到診斷，Quanterix 的超靈敏生物標誌物檢測推動了只有通過其無與倫比的靈敏度和靈活性才能實現的突破。公司的 Simoa®技術為血液、血清或血漿中更早的生物標誌物檢測提供了黃金標準，能夠量化遠低於定量水平（LoQ）的蛋白質。其行業領先的精密儀器、數字免疫測定技術和 CLIA 認證的加速實驗室支持了推動神經學、腫瘤學、免疫學、心臟病學和傳染病領域疾病理解和管理的研究。Quanterix 在近二十年裏一直是科學界值得信賴的合作伙伴，推動了在 3400 多本同行評審期刊上發表的研究。有關這家位於馬薩諸塞州比勒裏卡的公司的更多信息，請訪問 https://www.quanterix.com 或在 Twitter 和 LinkedIn 上關注我們。</p>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>本新聞稿中包含的非歷史性或不涉及當前事實的聲明旨在被視為前瞻性聲明，並在此被識別為根據《1933 年證券法》第 27A 條及《1934 年證券交易法》第 21E 條所提供的安全港條款。前瞻性聲明基於多種因素，包括對合並預期收益的預測，以及關於合併對 Quanterix 和 Akoya 的業務及未來財務和運營結果的影響，以及合併帶來的協同效應的數量和時間。諸如 “可能”、“大約”、“繼續”、“應該”、“期望”、“預測”、“預期”、“很可能”、“展望”、“相信”、“將”、“打算”、“估計”、“戰略”、“計劃”、“可以”、“潛在”、“可能” 等詞語及其變體旨在識別此類前瞻性聲明。Quanterix 提醒讀者，前瞻性聲明面臨某些風險和不確定性，這些風險和不確定性在時間、程度、可能性和發生的程度等方面難以預測，這可能導致實際結果與預期結果存在重大差異。這些風險和不確定性包括但不限於以下可能性：對 Quanterix 或 Akoya 可能提起的任何法律訴訟的結果；合併的預期收益和協同效應未能如期或根本未能實現的可能性，包括由於兩家公司整合過程中出現的問題或經濟和競爭因素的影響；管理層對持續業務運營和機會的注意力分散；合併完成後可能對業務或員工關係產生的不利反應或變化；合併完成後 Quanterix 股價的變化；與合併中發行的 Quanterix 普通股可能產生的稀釋效應相關的風險；以及可能影響合併公司未來結果的其他因素。可能導致結果與上述描述存在重大差異的其他因素可以在 Quanterix 截至 2024 年 12 月 31 日的年度報告（表格 10-K）及 Quanterix 向 SEC 提交的其他文件中找到，這些文件可在 SEC 網站 www.sec.gov 上獲取。</p>
<p>本新聞稿中所包含的所有前瞻性聲明，無論是明示還是暗示，均受到此處包含或提及的警示性聲明的完全限制。如果與這些或其他風險或不確定性相關的一個或多個事件發生，或者 Quanterix 的基本假設被證明不正確，實際結果可能與 Quanterix 的預期存在重大差異。Quanterix 提醒讀者不要對任何此類前瞻性聲明過度依賴，這些聲明僅在作出時有效，並基於當時可用的信息。除非聯邦證券法要求，Quanterix 不承擔更新或以其他方式修訂任何前瞻性聲明的義務，以反映前瞻性聲明作出後發生的情況或事件，或反映意外事件的發生。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MDc4MjgwNThyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MDc4MjgwNThyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20250707828058/en/</p>
<p>媒體</p>
<p>Marissa Klaassen</p>
<p>media@quanterix.com</p>
<p>投資者關係</p>
<p>Joshua Young</p>
<p>ir@quanterix.com</p>
<p>來源：Quanterix Corporation</p>

AKYA

QTRX

<p>Quanterix Corporation 已完成對 Akoya Biosciences 的收購，增強了其在神經學、腫瘤學和免疫學領域的生物標誌物檢測能力。該交易涉及發行約 780 萬股股票並支付 2000 萬美元現金。預計此次收購將使 Quanterix 的市場規模從 10 億美元擴大至 50 億美元，並在 2026 年之前加速盈利能力。關鍵任命包括 Scott Mendel 和 Dr. Myla Lai-Goldman 加入董事會。Quanterix 在交易後報告現金為 1.63 億美元，為未來增長奠定了基礎</p>

<p>07/08/2025 - 09:07 AM</p>
<div class="lb-trans"><p>2025 年 7 月 8 日- 上午 9:07</p>
</div><p>BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets.</p>
<div class="lb-trans"><p>馬薩諸塞州比勒裏卡 --（商業資訊）--Quanterix Corporation（“Quanterix” 或 “公司”）（納斯達克：QTRX），一家通過超靈敏生物標誌物檢測推動科學發現的公司，今天宣佈已完成之前宣佈的對 Akoya Biosciences, Inc.的收購，確立了在神經學、腫瘤學和免疫學市場早期疾病檢測的領先地位。</p>
</div><p>Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards.</p>
<div class="lb-trans"><p>根據 4 月 29 日宣佈的修訂合併協議，Quanterix 向 Akoya 的股東和其他 Akoya 股權獎勵持有者發行了約 780 萬股普通股，並支付了約 2000 萬美元的現金，總計。</p>
</div><p>Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said, “The acquisition of Akoya positions us to deliver comprehensive protein biomarker solutions that leverage signatures in blood and tissue, together providing a more holistic and predictive view of a patient’s disease. This transaction extends our portfolio into new markets and is expected to expand our served addressable market from $1 billion to $5 billion. We believe the combined business will benefit from significant scale, a strong balance sheet and an accelerated path to profitability by 2026.”</p>
<div class="lb-trans"><p>Quanterix 首席執行官 Masoud Toloue 博士表示：“收購 Akoya 使我們能夠提供全面的蛋白質生物標誌物解決方案，利用血液和組織中的特徵，提供對患者疾病的更全面和預測性的視角。這筆交易將我們的產品組合擴展到新市場，並預計將我們的可服務市場從 10 億美元擴大到 50 億美元。我們相信，合併後的業務將受益於顯著的規模、強大的資產負債表以及到 2026 年實現盈利的加速路徑。”</p>
</div><p><strong>Board and Management Appointments</strong></p>
<div class="lb-trans"><p><strong>董事會和管理層任命</strong></p>
</div><p>As previously announced, Masoud Toloue and Vandana Sriram will continue to serve as Chief Executive Officer and Chief Financial Officer of the combined company.</p>
<div class="lb-trans"><p>如之前所宣佈的，Masoud Toloue 和 Vandana Sriram 將繼續擔任合併公司的首席執行官和首席財務官。</p>
</div><p>Pursuant to the terms of the merger agreement, Akoya designated two of its directors, Scott Mendel and Myla Lai-Goldman, MD, to join the Quanterix Board of Directors, and Quanterix appointed Mr. Mendel and Dr. Lai-Goldman to its Board of Directors, effective at the closing of the transaction. Mr. Mendel brings over 30 years of financial and operational experience, most recently having served as CEO and President of GenMark Diagnostics. Dr. Lai-Goldman is a pioneer and leader in the diagnostics industry and has held various leadership roles at Labcorp and its predecessor company, Roche Biomedical Laboratories.</p>
<div class="lb-trans"><p>根據合併協議的條款，Akoya 指定了兩名董事 Scott Mendel 和 Myla Lai-Goldman 博士加入 Quanterix 董事會，Quanterix 在交易完成時任命 Mendel 先生和 Lai-Goldman 博士為其董事會成員。Mendel 先生擁有超過 30 年的財務和運營經驗，最近擔任 GenMark Diagnostics 的首席執行官和總裁。Lai-Goldman 博士是診斷行業的先驅和領導者，曾在 Labcorp 及其前身公司 Roche Biomedical Laboratories 擔任多個領導職務。</p>
</div><p>Mr. Mendel and Dr. Lai-Goldman will replace Martin D. Madaus, PhD, and Sarah Hlavinka, who have resigned from the Quanterix Board of Directors as of immediately prior to the closing of the transaction. Quanterix thanks Dr. Madaus and Ms. Hlavinka for their numerous contributions and dedication to the Company.</p>
<div class="lb-trans"><p>Mendel 先生和 Lai-Goldman 博士將取代在交易完成前立即辭去 Quanterix 董事會職務的 Martin D. Madaus 博士和 Sarah Hlavinka。Quanterix 感謝 Madaus 博士和 Hlavinka 女士對公司的諸多貢獻和奉獻。</p>
</div><p><strong>Balance Sheet</strong></p>
<div class="lb-trans"><p><strong>資產負債表</strong></p>
</div><p>At the time of closing the Akoya transaction, Quanterix had approximately $163 million in cash after repayment of Akoya’s debt and transaction-related costs.</p>
<div class="lb-trans"><p>在完成 Akoya 交易時，Quanterix 在償還 Akoya 債務和交易相關費用後，擁有約 1.63 億美元的現金。</p>
</div><p><strong>About Quanterix</strong></p>
<div class="lb-trans"><p><strong>關於 Quanterix</strong></p>
</div><p>From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.</p>
<div class="lb-trans"><p>從發現到診斷，Quanterix 的超靈敏生物標誌物檢測推動了只有通過其無與倫比的靈敏度和靈活性才能實現的突破。公司的 Simoa®技術為血液、血清或血漿中更早的生物標誌物檢測提供了黃金標準，能夠量化遠低於定量水平（LoQ）的蛋白質。其行業領先的精密儀器、數字免疫測定技術和 CLIA 認證的加速實驗室支持了推動神經學、腫瘤學、免疫學、心臟病學和傳染病領域疾病理解和管理的研究。Quanterix 在近二十年裏一直是科學界值得信賴的合作伙伴，推動了在 3400 多本同行評審期刊上發表的研究。有關這家位於馬薩諸塞州比勒裏卡的公司的更多信息，請訪問 https://www.quanterix.com 或在 Twitter 和 LinkedIn 上關注我們。</p>
</div><p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on, among other things, projections as to the anticipated benefits of the merger as well as statements regarding the impact of the merger on Quanterix’s and Akoya’s business and future financial and operating results and the amount and timing of synergies from the merger. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Quanterix cautions readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities: the outcome of any legal proceedings that may be instituted against Quanterix or Akoya; the possibility that the anticipated benefits and synergies of the merger are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business; diversion of management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the completion of the merger; changes in Quanterix’s share price after the closing of the merger; risks relating to the potential dilutive effect of shares of Quanterix common stock issued in the merger; and other factors that may affect future results of the combined company. Additional factors that could cause results to differ materially from those described above can be found in Quanterix’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and in other documents Quanterix files with the SEC, which are available on the SEC’s website at www.sec.gov.</p>
<div class="lb-trans"><p>本新聞稿中包含的非歷史性或不涉及當前事實的聲明旨在被視為前瞻性聲明，並在此被識別為根據《1933 年證券法》第 27A 條及《1934 年證券交易法》第 21E 條所提供的安全港條款。前瞻性聲明基於多種因素，包括對合並預期收益的預測，以及關於合併對 Quanterix 和 Akoya 的業務及未來財務和運營結果的影響，以及合併帶來的協同效應的數量和時間。諸如 “可能”、“大約”、“繼續”、“應該”、“期望”、“預測”、“預期”、“很可能”、“展望”、“相信”、“將”、“打算”、“估計”、“戰略”、“計劃”、“可以”、“潛在”、“可能” 等詞語及其變體旨在識別此類前瞻性聲明。Quanterix 提醒讀者，前瞻性聲明面臨某些風險和不確定性，這些風險和不確定性在時間、程度、可能性和發生的程度等方面難以預測，這可能導致實際結果與預期結果存在重大差異。這些風險和不確定性包括但不限於以下可能性：對 Quanterix 或 Akoya 可能提起的任何法律訴訟的結果；合併的預期收益和協同效應未能如期或根本未能實現的可能性，包括由於兩家公司整合過程中出現的問題或經濟和競爭因素的影響；管理層對持續業務運營和機會的注意力分散；合併完成後可能對業務或員工關係產生的不利反應或變化；合併完成後 Quanterix 股價的變化；與合併中發行的 Quanterix 普通股可能產生的稀釋效應相關的風險；以及可能影響合併公司未來結果的其他因素。可能導致結果與上述描述存在重大差異的其他因素可以在 Quanterix 截至 2024 年 12 月 31 日的年度報告（表格 10-K）及 Quanterix 向 SEC 提交的其他文件中找到，這些文件可在 SEC 網站 www.sec.gov 上獲取。</p>
</div><p>All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.</p>
<div class="lb-trans"><p>本新聞稿中所包含的所有前瞻性聲明，無論是明示還是暗示，均受到此處包含或提及的警示性聲明的完全限制。如果與這些或其他風險或不確定性相關的一個或多個事件發生，或者 Quanterix 的基本假設被證明不正確，實際結果可能與 Quanterix 的預期存在重大差異。Quanterix 提醒讀者不要對任何此類前瞻性聲明過度依賴，這些聲明僅在作出時有效，並基於當時可用的信息。除非聯邦證券法要求，Quanterix 不承擔更新或以其他方式修訂任何前瞻性聲明的義務，以反映前瞻性聲明作出後發生的情況或事件，或反映意外事件的發生。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MDc4MjgwNThyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250707828058r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20250707828058/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20250707828058/en/</p>
</div><p>Media</p>
<div class="lb-trans"><p>媒體</p>
</div><p>Marissa Klaassen</p>
<div class="lb-trans"><p>Marissa Klaassen</p>
</div><p>media@quanterix.com</p>
<div class="lb-trans"><p>media@quanterix.com</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>Joshua Young</p>
<div class="lb-trans"><p>Joshua Young</p>
</div><p>ir@quanterix.com</p>
<div class="lb-trans"><p>ir@quanterix.com</p>
</div><p>Source: Quanterix Corporation</p>
<div class="lb-trans"><p>來源：Quanterix Corporation</p>
</div>

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | QTRX Stock News

Quanterix 完成了對 Akoya Biosciences 的收購，打造了首個能夠在血液和組織連續體中測量生物標誌物的綜合平台 | QTRX 股票新聞